Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)

Patent metadata

Field	Value
Publication number	US-9724425-B2
Application number	US-201414482703-A
Country	US
Kind code	B2
Filing date	Sep 10, 2014
Priority date	Dec 22, 2004
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.

First claim

What is claimed:

1. A conjugate comprising an IGF-I (insulin-like growth factor I) variant and poly(ethylene glycol), wherein the IGF-I variant has amino acid alterations from wild-type IGF-I at positions 27 and 65 or at positions 27 and 68, and the amino acid alterations do not reduce in vitro binding affinity for an IGF-I binding protein and in vitro IGF-I receptor phosphorylation; wherein the IGF-I variant selected from the group consisting of R27, R37, R65, K68 (RRRK) and R27, R37, K65, R68 (RRKR) and wherein the poly(ethylene glycol) is conjugated to the IGF-1 variant via a lysine primary amino group without poly(ethylene glycol) being conjugated to the N-terminus of the IGF-I variant.

2. The conjugate according to claim 1 wherein the poly(ethylene glycol) has an overall molecular weight of from 20 to 100 kDa.

3. The conjugate according to claim 1 wherein the IGF-I variant is RRRK and conjugated to poly(ethylene glycol) at K68.

4. The conjugate according to claim 1 wherein up to three amino acids at the N-terminus are truncated.

5. The conjugate according to claim 1 wherein the poly(ethylene glycol) is branched.

6. A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.

Assignees

• Hoffmann La Roche
• Kerstin Kruger

Inventors

• Amrein Beat
• Foser Stefan
• Lang Kurt
• Metzger Friedrich
• Regula Joerg Thomas
• Schaubmar Andreas
• Hesse Friederike
• Kuenkele Klaus-Peter
• Lanzendoerfer Martin

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K47/60 Primary

  the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title

• A61K38/30 Primary

  Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)} · CPC title

• C07K19/00

  Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title